UAB Digital Repository of Documents 7 records found  Search took 0.00 seconds. 
1.
9 p, 1.7 MB KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust) ; Chau, Ian (The Royal Marsden NHS Foundation Trust) ; Cunningham, David (The Royal Marsden NHS Foundation Trust) ; Hahne, Jens Claus (The Institute of Cancer Research) ; Vlachogiannis, George (The Institute of Cancer Research) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust) ; Lampis, Andrea (The Institute of Cancer Research) ; Braconi, Chiara (The Institute of Cancer Research) ; Kalaitzaki, Eleftheria (The Royal Marsden NHS Foundation Trust) ; De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust) ; Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Glimelius, Bengt (University of Uppsala) ; Tarazona, Noelia (Universitat de València) ; Begum, Ruwaida (The Royal Marsden NHS Foundation Trust) ; Lote, Hazel (The Institute of Cancer Research) ; Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust) ; Mentrasti, Giulia (The Institute of Cancer Research) ; Brown, Gina (The Royal Marsden NHS Foundation Trust) ; Tait, Diana (The Royal Marsden NHS Foundation Trust) ; Oates, Jacqueline (The Royal Marsden NHS Foundation Trust) ; Valeri, Nicola (The Institute of Cancer Research) ; Universitat Autònoma de Barcelona
There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. [...]
2018 - 10.1038/s41598-018-19212-5
Scientific reports, Vol. 8 (january 2018)  
2.
17 p, 1.9 MB 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial / Iveson, Timothy J. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ; Kerr, Rachel S. (Department of Oncology, University of Oxford, Oxford, UK) ; Saunders, Mark P. (The Christie Hospital, Manchester, UK) ; Cassidy, Jim (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Hollander, Niels Henrik (Westmead Hospital) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Haydon, Andrew (Australasian Gastro-Intestinal Trials Group, Melbourne, VIC, Australia) ; Glimelius, Bengt (IGP, University of Uppsala, Uppsala, Sweden) ; Harkin, Andrea (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Allan, Karen (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; McQueen, John (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Scudder, Claire (OCTO, University of Oxford, Department of Oncology, Oxford, UK) ; Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ; Briggs, Andrew (Memorial Sloan-Kettering Cancer Centre) ; Waterston, Ashita (Beatson West of Scotland Cancer Centre (Glasgow, Regne Unit)) ; Medley, Louise (Royal United Hospital, Bath, UK) ; Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Ellis, Richard (Royal Cornwall Hospital NHS Trust, Truro, UK) ; Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK) ; Dhadda, Amandeep S. (Castle Hill Hospital) ; Harrison, Mark (Mount Vernon Cancer Centre, Northwood, UK) ; Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ; Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ; Rees, Charlotte (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ; Olesen, Rene K. (Aarhus University Hospital (Aarhus, Dinamarca)) ; Propper, David (Barts Cancer Institute (BCI)) ; Bridgewater, John (UCL Cancer Institute, University College London, London UK) ; Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK) ; Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK) ; Webb, Andrew (Brighton and Sussex University Hospital Trust) ; Cunningham, David (Royal Marsden Hospital (Regne Unit)) ; Hickish, Tamas (Poole Hospital, Bournemouth University, Bournemouth, UK) ; Weaver, Andrew (Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK) ; Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ; Wasan, Harpreet S.. (Hammersmith Hospital (Londres)) ; Paul, James (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. [...]
2018 - 10.1016/S1470-2045(18)30093-7
The Lancet. Oncology, Vol. 19 (april 2018) , p. 562-578  
3.
7 p, 434.6 KB SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer / Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ; Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ; Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ; Iveson, Timothy (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ; Kerr, Rachel S. (University of Oxford. Department of Oncology) ; Saunders, Mark P. (The Christie Hospital) ; Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Hollander, Niels Henrik (Zealand University Hospital) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ; Glimelius, Bengt (University of Uppsala) ; Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ; Waterston, Ashita (Beatson West of Scotland Cancer Centre (Glasgow, Regne Unit)) ; Medley, Louise (Royal United Hospital) ; Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ; Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ; Dhadda, Amandeep S. (Castle Hill Hospital) ; Hughes, Rob (Mount Vernon Cancer Centre) ; Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ; Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ; Rees, Charlotte (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ; Olesen, Rene K. (Zealand University Hospital) ; Propper, David (Barts Cancer Institute (BCI)) ; Bridgewater, John (University College London) ; Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ; Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ; Webb, Andrew (Brighton and Sussex University Hospital Trust) ; Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ; Hickish, Tamas (Poole Hospital/Bournemouth University) ; Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ; Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ; Wasan, Harpreet S.. (Hammersmith Hospital (Londres)) ; Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 - 10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338  
4.
8 p, 196.5 KB Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer / Sclafani, Francesco (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Brown, Gina (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Cunningham, David (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Wotherspoon, Andrew (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Mendes, Larissa Sena Teixeira (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Balyasnikova, Svetlana (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Evans, Jessica (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Peckitt, Clare (Clinical Research & Development, The Royal Marsden NHS Foundation Trust) ; Begum, Ruwaida (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tait, Diana (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Glimelius, Bengt (Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, University of Uppsala) ; Roselló, Susana (Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia) ; Thomas, Janet (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Oates, Jacqui (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Chau, Ian (Department of Medicine, The Royal Marsden NHS Foundation Trust)
Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). [...]
2017 - 10.1038/bjc.2017.320
British Journal of Cancer, Vol. 117 (09 2017) , p. 1478-1485  
5.
7 p, 814.0 KB Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma : results from a randomised controlled trial / Siena, Salvatore (Università degli Studi di Milano (Italy)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Bodoky, Gyorgy (St László Hospital (Hongria)) ; Cunningham, David (Royal Marsden National Health Service Foundation Trust (United Kingdom)) ; Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Ruff, Paul (University of the Witwatersrand (South Africa)) ; Canon, Jean Luc (Grand Hôpital de Charleroi. Service d'Oncologie-Hématologie (Belgium)) ; Koukakis, Reija (Amgen Ltd. Department of Biostatistics (United Kingdom)) ; Demonty, Gaston (Amgen GmbH. Medical Development (Suïssa)) ; Hechmati, Guy (Amgen GmbH. Global Health Economics (Suïssa)) ; Douillard, Jean-Yves (Institut de Cancérologie de l'Ouest (France)) ; Universitat Autònoma de Barcelona
Metastatic colorectal cancer is rarely curable. Improving quality of life is therefore a key treatment goal. We report quality of life for patients with RAS wild-type metastatic colorectal cancer in the PRIME study. [...]
2016 - 10.1136/esmoopen-2016-000041
ESMO open, Vol. 1, Issue 2 (March 2016) , art. e000041  
6.
6 p, 1.4 MB Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Lampis, Andrea (The Institute of Cancer Research. Department of Molecular Pathology) ; Hahne, Jens Claus (The Institute of Cancer Research. Department of Molecular Pathology) ; Ghidini, Michele (The Institute of Cancer Research. Department of Molecular Pathology) ; Lote, Hazel (The Institute of Cancer Research. Department of Molecular Pathology) ; Zito, Domenico (The Institute of Cancer Research. Department of Molecular Pathology) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Glimelius, Bengt (University of Uppsala. Genetics and Pathology, Experimental and Clinical Oncology. Department of Immunology) ; Cervantes, Andrés (University of Valencia. Biomedical Research Institute INCLIVA. Department of Haematology and Medical Oncology) ; Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Wilson, Sanna Hulkki (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Peckitt, Clare (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Tait, Diana (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Oates, Jacqueline (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Braconi, Chiara (The Institute of Cancer Research. Department of Cancer Therapeutics) ; Valeri, Nicola (The Institute of Cancer Research. Department of Molecular Pathology) ; Universitat Autònoma de Barcelona
Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab. [...]
2016 - 10.1093/carcin/bgw073
Carcinogenesis, Vol. 37 (july 2016) , p. 852-857  
7.
6 p, 225.1 KB Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Lampis, Andrea (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Hahne, Jens Claus (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Braconi, Chiara (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ; Cervantes, Andrés (Universitat de València. Departament d'Hematologia i Oncologia Mèdica) ; Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; González De Castro, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Valeri, Nicola (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941  

See also: similar author names
1 Cunningham, D.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.